Effects of elevated serum urate on cardiometabolic and kidney function markers in a randomised clinical trial of inosine supplementation

• Published in: Scientific reports 2022-07, Vol.12 (1), p.12887-12887, Article 12887
• Main Authors: Dalbeth, Nicola, Mihov, Borislav, Stewart, Angela, Gamble, Gregory D., Merriman, Tony R., Mount, David, Reid, Ian R., Stamp, Lisa K., Horne, Anne
• Format: Article
• Language: English
• Subjects: 692/4022; 692/53; ACTRN; ACTRN12617000940370; Blood pressure; Body mass index; C-reactive protein; Clinical trials; Creatinine; Epidermal growth factor receptors; Glomerular filtration rate; Humanities and Social Sciences; Hyperuricemia; Insulin; Kidney diseases; Kidneys; Menopause; multidisciplinary; Observational studies; Placebos; Post-menopause; Science; Science (multidisciplinary); Supplements; Uric acid
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-17257-1

In observational studies, serum urate positively associates with cardiometabolic and kidney diseases. We analyzed data from a randomised placebo-controlled trial to determine whether moderate hyperuricemia induced by inosine affects cardiometabolic and kidney function markers. One hundred and twenty post-menopausal women were recruited into a 6-month randomised, double-blind, placebo-controlled trial of inosine for bone health. Change from baseline in the following pre-specified endpoints was analyzed: body mass index; blood pressure; lipid profile; C-reactive protein; fasting glucose; insulin; HbA1c; serum creatinine; and estimated glomerular filtration rate (eGFR). Despite increases in serum urate levels (+ 0.17 mmol/L at week 6, P